Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Skin Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × Ascorbic Acid × Clear all
NCT05174845 2022-05-31

Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia

Norgine

Completed
13,393 enrolled
Gastrointestinal

Colonic Diseases, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡